Study S002828

A Randomized, Double-Blind, Crossover Phase I Clinical Study to Evaluate the Safety, Tolerability, PK and PD Profiles of a Single Dose of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects

ClinicalTrials.gov record

Registration

Registration: NCT06974487
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: NOT_YET_RECRUITING
Enrollment: 30
Start: 2025-05-08
Primary completion: 2025-09-30
Lead sponsor: Gan & Lee Pharmaceuticals.
Conditions: Type 2 Diabetes
Interventions: DRUG:GZR102 injection; DRUG:GZR4 injection; DRUG:GZR18 injection
Results posted: FALSE

Registered primary outcomes

AUC0-t [Day 36 (end of period)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.